Startup profile · funding coverage
Microbiotica funding, valuation and investors
Clinical-stage developer of oral precision microbiome medicines.
Keep track of Microbiotica
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series C — first close
£36M / $48M · October 16, 2026
Latest known valuation
Not publicly disclosed
Total disclosed equity funding
$48M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
growth · Chesterford Research Park, near Cambridge, United Kingdom
Investors in latest funding
Lead: British Business Bank
Other: Tencent , IP Group , Cambridge Innovation Capital , Flerie Invest , Seventure Partners
Overview
Microbiotica is a private clinical-stage biopharma company spun out of the Wellcome Sanger Institute in 2016, based at Chesterford Research Park near Cambridge. It develops live biotherapeutic products informed by genomic analysis of gut bacteria. Its lead asset MB310 targets ulcerative colitis; MB097 is under clinical evaluation with pembrolizumab for advanced melanoma.
Why Microbiotica is interesting
Its £36 million Series C first close funds a larger clinical test of MB310 after company-reported Phase 1b signals. The investment thesis depends on reproducible patient benefit, consistent bacterial manufacturing and a clinically differentiated product—not merely platform breadth.
Product & use cases
A genomics-driven platform identifies bacterial signatures associated with favorable trial outcomes in specific patient groups and selects strains for development as oral medicines. MB310 comprises eight live bacterial strains; it remains investigational.
Key facts
- Oct 16, 2026: £36M/$48M Series C first close led by British Business Bank
- All existing Series B investors participated; valuation and final target undisclosed
- Proceeds support MB310's planned Phase 2 study in ulcerative colitis
- MB097 is also being evaluated in an early-stage melanoma study; neither program is an approved treatment
Funding history (newest first)
Series C — first close
2026-10-16 £36M / $48MInvestors in our directory
Funds linked from Microbiotica's profile — open a fund page for stage focus and related deal articles.
Competitive landscape
Edge: A clinical-data-led strain selection approach, an investigational pipeline and purpose-built development capabilities may differentiate the company; comparative efficacy and manufacturing economics are not yet established.
Microbiotica competes with other microbiome developers and established treatments in its target indications. Evidence from larger controlled trials, durability, tolerability and manufacturing consistency will matter more than investor branding.
Industries
Market / IPO context
Editorial / static context — not a live quote.
Related funding articles
Venture Capital Tracker pieces that cover Microbiotica's financing or category context.
FAQs about Microbiotica
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.